The Priority Review

The stream · Daily digest

The stream: Wednesday, October 14, 2026

5 briefs from ClinicalTrials.gov and FDA, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 3

  1. Almirall registers Phase 3b trial of lebrikizumab in face and neck atopic dermatitis

    The study plans to enroll 230 participants and is expected to start in November 2026. It aims to evaluate the efficacy and safety of lebrikizumab for up to 32 weeks in adults and adolescents with moderate-to-severe face and neck atopic dermatitis who also have moderate-to-severe AD elsewhere and need systemic therapy.

    Source: ClinicalTrials.gov registry record, October 14, 2026

  2. Ultragenyx posts results of Phase 3 DTX401 trial in Glycogen Storage Disease Type Ia

    The study enrolled 52 participants and completed primary data collection on February 20, 2024. It evaluated DTX401's ability to reduce or eliminate dependence on exogenous glucose replacement therapy and to improve glucose control quality.

    Source: ClinicalTrials.gov results record, October 14, 2026

  3. Hoffmann-La Roche posts results of Phase 3 obinutuzumab trial in childhood nephrotic syndrome

    The study, completed in September 2025, enrolled 85 participants aged 2-25 years and compared obinutuzumab with mycophenolate mofetil. Results were first posted on ClinicalTrials.gov on October 14, 2026.

    Source: ClinicalTrials.gov results record, October 14, 2026

Approvals · 1

  1. FDA approves expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive NMIBC

    On October 14, 2026, the FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer, adding high-grade papillary-only tumors to the prior indication for carcinoma in situ. The approval is based on efficacy data from Cohort A of QUILT-3.032, which showed a 62% complete response rate (95% CI: 51, 73).

    Source: FDA approval notification, October 14, 2026

Regulation · 1

  1. FDA launches Rare Disease Framework Initiative to gather public feedback

    The FDA announced the Rare Disease Framework Initiative on October 14, 2026, aiming to create a fit-for-purpose framework for rare disease drug development. It will host an October 28 meeting at its White Oak campus to solicit feedback from patients, advocates, and industry.

    Source: FDA press announcement, October 14, 2026